The effect of weight on the efficacy of biologic therapy in patients with psoriasis - 24/04/13
Reprint requests: Mark Lebwohl, MD, Department of Dermatology, Mount Sinai School of Medicine, 5 E 98th St, 5th Floor, New York, NY 10029.Abstract |
Background |
The prevalence of obesity is rapidly increasing in the United States. Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight.
Objective |
We attempted to determine whether the efficacy of the biologics is affected by weight.
Methods |
We review the existing body of literature, including subgroup analyses, relating to efficacy and weight for infliximab, efalizumab, alefacept, and etanercept. No relevant literature was found for adalimumab.
Results |
Weight-based dosed medications do not seem to lose efficacy with increasing weight. Both etanercept and alefacept may have compromised efficacy in heavier individuals.
Limitations |
The data are limited to subgroup analyses and smaller studies, often with no statistical significance reported.
Conclusions |
Additional studies are warranted, specifically designed to address the issue of obesity and response to therapy of the biologics. Alternative dosing for etanercept and alefacept should be further evaluated in patients above normal weight
Le texte complet de cet article est disponible en PDF.Abbreviations used : BMI, FDA, PASI, SC, TNF
Plan
| Funding sources: None. |
|
| Disclosure: In the last 12 months, members of Dr Lebwohl’s department have served at the drug companies listed below. Dr Lebwohl is also a consultant (or has pending agreements) for Abbott, Amgen, Astellas, Biogen Idec, Centocor, Connetics, Genentech, Novartis, Pfizer, Warner Chilcott, and 3M. In addition, members of Mount Sinai’s Department of Dermatology hold patents for short-contact tazarotene therapy, excimer laser treatment vitiligo, and topical genistein. Finally, in the last 12 months, Dr Lebwohl has served as speaker for Abbott, Allergan, Amgen, Astellas, Biogen Idec, Centocor, Connetics, Novartis, Warner Chilcott, and 3M. Dr Clark has no conflicts of interest to declare. |
Vol 58 - N° 3
P. 443-446 - mars 2008 Retour au numéro
Article précédent
- CXCR3 <-> ligand–mediated skin inflammation in cutaneous lichenoid graft-versus-host disease
- Joerg Wenzel, Svenja Lucas, Sabine Zahn, Sandra Mikus, Dieter Metze, Sonja Ständer, Esther von Stebut, Uwe Hillen, Thomas Bieber, Thomas Tüting
- The use of blood-type tattoos during the Cold War
- Elizabeth K. Wolf, Anne E. Laumann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?